Compared to osimertinib, Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) significantly extended overall survival.

Leveraging artificial intelligence-powered stochastic methods for clinical data review represents a significant leap beyond ...

In this video interview, Rachael Higgins, chief commercial officer, PicnicHealth, highlights how addressing these challenges ...

In this video interview, Rachael Higgins, chief commercial officer, PicnicHealth, discusses findings from the report and the ...

FDA grants Priority Review status to Sanofi's tolebrutinib for the treatment of non-relapsing secondary progressive multiple ...

Andrew Mackinnon, Executive GM, Medable, explains how the company’s recent approval in France could support the expansion of ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

In this video interview, Cameron Breze, product manager, Inovalon, highlights current trends with decentralization and how a ...

Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...

In this video interview, Rachael Higgins, chief commercial officer, PicnicHealth, talks traditional research methods in clinical trials and why industry leaders remain reliant on them.

Andrew Mackinnon, executive GM, Medable, explains how the company ensures high patient participation and data accuracy in ...

In today’s clinical trials, compared to those of the past, there is increasing complexity, greater data collection, and a ...